Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience
- 24 April 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 61 (2), 109-112
- https://doi.org/10.1111/j.1600-0609.1998.tb01069.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress [editorial]Blood, 1994
- Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomyBritish Journal of Cancer, 1993
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patientsBlood, 1993
- Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.BMJ, 1990
- Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987Blood, 1989
- Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabineBlood, 1988
- RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE: Relation to Age, Cumulative Dose of Alkylating Agents, and Time from ChemotherapyThe Lancet, 1987
- Acute nonlymphocytic leukemia.A delayed complication of Hodgkin's disease therapy: Analysis of 109 casesCancer, 1977
- Leukemia and Hodgkin's DiseaseAnnals of Internal Medicine, 1963